The Takeover of Monsanto has weakened the Bayer stock significantly, revenues and earnings of the group given a hefty boost. However, high depreciation charge in the business with over-the-counter health products. And the number of glyphosate-applicants grows.
the bottom line of the profit of Bayer broke last year, around three-quarters to € 1.7 billion. This mainly includes the depreciation of EUR 2.7 billion on goodwill in the business with over-the-counter drugs, Bayer plans to separate. To do this, the only a few years ago expensive from the US competitor Merck & Co acquired the area of sun protection with the brand, Coppertone, and the foot care brand Dr. Scholl’s.
sales increased thanks to the Monsanto Acquisition in the past year, around 13 per cent to 39.6 billion euros. The earnings before interest, taxes, depreciation and amortization (Ebitda) and before special items rose only slightly by 2.8 percent to 9.5 billion euros, also because of the costs of rectifying problems as a result of a complaint by the US health authority FDA were incurred.
number of plaintiffs
Meanwhile, risen has increased the number of plaintiffs against Bayer due to the herbicide, glyphosate. Up to the 28. January is the daughter of Monsanto in the USA had been complaining of approximately 11,200 applicants, informed Bayer now. Finally, this number was of 9,300 claimants. Bayer had been served in January, in addition, a canadian lawsuit in connection with the gylphosat-containing herbicide Roundup from Monsanto on the approval of a class action suit was sought, it was said in the annual report.
for More price information of the Bayer group
is Significant as the first method of the in of the this week, launched the process of another plaintiff. Because it is the first case that will be heard by a Federal district court and is part of a mass process. Bayer denies the allegations and refers to the fact that admission authorities rated the world’s glyphosate when used properly as safe.
problems on several fronts
Bayer is currently fighting on several fronts. The last year for around 63 billion dollars acquired Seed company Monsanto needs to be integrated. That alone is a feat of strength, to make matters worse, the wave of lawsuits in the United States because of alleged cancer risk from glyphosate.
Headquarters of Bayer AG in Leverkusen, Germany
investors are nervous after the seed giant had collected in the past year, a bitter defeat in front of a U.S. court and sentenced to a compensation in the three-digit million amount. It is chosen however, nothing; Bayer appealed. Monsanto and glyphosate are not the only sites.
Waiting for new box-office hit
The non-prescription medicines business is running sluggish and in the pharmaceutical business, investors are waiting on the next box-office hit, also because of the major sales is threatening to providers, such as the anticoagulant Xarelto and the eye drug Eylea in a couple of years to generic competition. After all, it was the last positive news: in the face of good trial data, the chances for approval of the cancer drug candidate Darolutamid are increased. For the cancer hope Larotrectinib Bayer also secured the exclusive marketing rights, after the research partner Loxo Oncology was swallowed up by the competition.
all in All, a waste of Bayer rubbed in the face of the many problems a program to increase efficiency, to save costs and to streamline the workflow. Should elimination of approximately 12,000 Positions.
The reaction of investors, however, are clear: After you came in premarket trading slightly under pressure to put the shares in a regular Xetra trade against the Trend by a good three per cent. Traders praised the good results in the agricultural business.
lg/rtr/dpa
source: boerse.ard.de
investors are wheezing by Bayer: Billion-dollar depreciation and a lot of actions Beiersdorf: Rude awakening of the stock market
